CJC-1295 (No DAC) combined with Ipamorelin is a synergistic research peptide blend widely utilized in laboratory and preclinical settings to investigate pulsatile growth hormone (GH) release and hypothalamic–pituitary axis signaling. This dual-compound formulation is designed to evaluate the interaction between short-acting GHRH analogs and selective ghrelin receptor agonists in controlled experimental environments.
 
CJC-1295 (without DAC) functions as a short-acting GHRH analog, commonly studied for its ability to promote natural GH pulse amplification with precise temporal control. Ipamorelin, a selective growth hormone secretagogue, is researched for its targeted stimulation of GH release via ghrelin receptor pathways, with minimal interaction with cortisol or prolactin signaling in experimental models.
 
Together, this combination is frequently investigated for its role in:
Growth hormone pulsatility and endocrine signaling
IGF-1 pathway modulation
Metabolic regulation and energy utilization
Tissue repair and recovery pathway research
Age-related endocrine function models
 
The absence of DAC allows for more controlled observation of GH release patterns, making this blend particularly useful in studies requiring timing-specific pathway analysis.
 
This high-purity 5mg/5mg formulation is manufactured to strict laboratory standards and intended exclusively for analytical testing, in-vitro studies, and experimental research applications.
 
For research use only. Not for human consumption.
 
 
See product pictures for Certificates of Analysis.